Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Finished Goods: 2017-2024

Historic Finished Goods for RedHill Biopharma (RDHL) over the last 8 years, with Dec 2024 value amounting to $2.8 million.

  • RedHill Biopharma's Finished Goods fell 14.96% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year decrease of 14.96%. This contributed to the annual value of $2.8 million for FY2024, which is 14.96% down from last year.
  • As of FY2024, RedHill Biopharma's Finished Goods stood at $2.8 million, which was down 14.96% from $3.3 million recorded in FY2023.
  • RedHill Biopharma's 5-year Finished Goods high stood at $6.8 million for FY2022, and its period low was $2.8 million during FY2024.
  • Moreover, its 3-year median value for Finished Goods was $3.3 million (2023), whereas its average is $4.3 million.
  • As far as peak fluctuations go, RedHill Biopharma's Finished Goods surged by 1,521.23% in 2020, and later tumbled by 51.25% in 2023.
  • Over the past 5 years, RedHill Biopharma's Finished Goods (Yearly) stood at $4.7 million in 2020, then soared by 39.48% to $6.6 million in 2021, then grew by 3.39% to $6.8 million in 2022, then tumbled by 51.25% to $3.3 million in 2023, then dropped by 14.96% to $2.8 million in 2024.